Skip to content
BiologicalX

Dosage guide

CJC-1295 dosage

CJC-1295 dosing: typical range, frequency, half-life, onset, routes, reconstitution math. Evidence-tiered.

At a glance

Typical dose
0.1mg
Half-life
168hr
Frequency
weekly (DAC); 1-3x daily (non-DAC)
Routes
subcutaneous

Protocol

  1. 1

    Reconstitute the vial

    A typical 2 mg vial reconstituted with 2 mL bacteriostatic water gives 1 mg/mL (1000 mcg/mL). A 100 mcg dose equals 10 units on a U100 insulin syringe. DAC variant is dosed weekly to twice weekly; non-DAC is dosed 1 to 3 times daily.

    Open tool →
  2. 2

    Measure the dose

    Typical CJC-1295 dose is 0.1 mg (DAC: 1 to 2 mg weekly. Non-DAC: 100 mcg 1 to 3 times daily, often pre-bed and post-workout.). Use a weight-based calculator for individual adjustments.

    Open tool →
  3. 3

    Set the frequency

    Administer weekly (DAC); 1-3x daily (non-DAC). Half-life of 168 hours anchors the dosing interval.

    Open tool →
  4. 4

    Cycle if needed

    Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.

    Open tool →
  5. 5

    Monitor for side effects

    Watch for: injection-site reactions; water retention; numbness or tingling at injection site; vivid dreams. Stop or reduce dose if tolerability breaks down.

Why this dose

Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond.

The typical dose (0.1 mg) reflects DAC: 1 to 2 mg weekly. Non-DAC: 100 mcg 1 to 3 times daily, often pre-bed and post-workout.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

CJC-1295 is administered via the subcutaneous route. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 1 hour after administration. Peak effect lands near 3 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: DAC variant ~7 day half-life via albumin tether. Non-DAC (Mod GRF 1-29) ~30 minute half-life produces pulsatile GH release closer to physiology.

Cycling and tolerance

Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

  • GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
  • DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
  • Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
  • Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
  • Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
  • No completed phase III RCTs; research-use-only and not FDA approved

Best-graded outcomes

  • B IGF-1 elevation : 2 to 10 fold rise sustained for ~7 days at DAC dose (Healthy adults, Teichman 2006).
  • B Mean GH and pulsatile GH amplitude : Sustained GH elevation at supraphysiologic levels (Healthy adults, Teichman 2006).
  • C Body composition (lean mass, fat loss) : Inferred from IGF-1 axis activation; not directly measured (Anecdotal user reports; no controlled trial).

Side effects and interactions

Common side effects

  • injection-site reactions
  • water retention
  • numbness or tingling at injection site
  • vivid dreams
  • transient flushing

Notable interactions

  • insulin (moderate): GH-induced insulin resistance can shift glycemic control over weeks
  • corticosteroids (moderate): blunt GH-axis response; reduce expected efficacy
  • Ipamorelin (minor): synergistic GH release; commonly co-administered in anecdotal protocols

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full CJC-1295 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status
banned
DEA / Rx
Not FDA approved; not scheduled; research-chemical status
Pregnancy
Insufficient data; not recommended
Legal status
Not FDA approved; research-use-only grey market; banned by WADA

Do not use if

  • pregnancy
  • active malignancy
  • diabetic retinopathy (theoretical)
  • history of pituitary tumor

Related calculators

Weight-based dosage calculator → Half-life timeline → Reconstitution calculator → Cost per dose →

Related research

CJC-1295 full profile → All dosage guides →